In This Section

Stewart A. Anderson, MD
Stewart A. Anderson
Director of Research, Department of Child and Adolescent Psychiatry and Behavioral Services

Dr. Anderson’s research interests focus on the molecular and cellular mechanisms that govern the development of the mammalian forebrain. In his research on the development of the cerebral cortex, he is particularly interested in understanding the molecular underpinnings behind the fate determination and axon targeting of subclasses of GABAergic interneurons implicated in the neuropathology of schizophrenia.

AddtoAny
Share:

Bio

Dr. Anderson serves as director of research in the Department of Child and Adolescent Psychiatry and Behavioral Services and associate director of the Lifespan Brain Institute, a CHOP-Penn collaboration dedicated to identifying the neuropathological antecedents of neuropsychiatric disease.

He has a longstanding interest in the interface between basic science and clinical research, and his research has involved the development of the cerebral cortex and schizophrenia.

Dr. Anderson's current research involves the molecular and cellular mechanisms that govern the development of the mammalian forebrain. Using mouse genetics, forebrain slice and dissociated culture techniques, as well as mouse and human embryonic stem cells in cell culture and transplantation experiments, he and his lab team study the development of the cerebral cortex. They are particularly interested in understanding the molecular underpinnings behind the fate determination and axon targeting of subclasses of GABAergic interneurons implicated in the neuropathology of schizophrenia.

New research directions by Dr. Anderson and his lab include the study of mitochondria in interneuron migration, maturation, and function. In addition, they are generating mouse and human stem cell-derived interneurons for use in cell-based therapies for seizures, psychotic disorders, and as tools for the study of gene-gene and gene-environment interactions in neuropsychiatric disease.

Education and Training

BA, Amherst College (Neuroscience), 1984

MD, University of Connecticut School of Medicine, 1989

Fellowship, University of California, San Francisco (Neurogenetics), 1998

Titles and Academic Titles

Director of Research, Department of Child and Adolescent Psychiatry and Behavioral Services

Associate Director, The Lifespan Brain Institute of Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine

Co-Leader, Developmental Biology Research Affinity Group

Professor of Psychiatry

Professional Memberships

Society for Neuroscience, 1993-

Brain and Behavior Research Foundation (formerly NARSAD), 2009-

Professional Awards

Freedman Award, National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD), 1999

American College of Neuropsychopharmacology Travel Award, 1999

Future Leaders in Psychiatry Award, Emory University, 2002

National Alliance for Research in Schizophrenia and Affective Disorders Young Investigator Award, 2002

Freedman Award, NARSAD, honorable mention, 2006

Publication Highlights

Li J, Ryan SK, Deboer E, Cook K, Fitzgerald S, Lachman HM, Wallace DG, Goldberg EM, Anderson SA. Mitochondrial deficits in human iPSC-derived neurons from patients with 22q11.2 deletion syndrome and schizophrenia. Translational Psychiatry. 2019 Nov; 9(1):302. PMC6861238
Guo Y, Singh L, Gur RE, Anderson SA, Alvarez JI. Association of a Functional Claudin-5 Variant with Schizophrenia in Female Patients with the 22q11.2 Deletion Syndrome. Schizophrenia Research. 2019 Oct; In Press
Ryan SK, Gonzalez MV, Garifallou JP, Bennett FC, Williams KS, Sotuyo NP, Mironets E, Cook K, Hakonarson H, Anderson SA*, Jordan-Sciutto KL*. Neuroinflammation and EIF2 signaling persist despite antiretroviral treatment in an HiPSC tri-culture model of HIV infection. Stem Cell Research . 2019 Sep; (*co-corresponding authors). In Press
Donegan JJ, Tyson JA, Branch SY, Beckstead MJ, Anderson SA, Lodge DJ. Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model. Mol Psychiatry. 2017 Oct; 22(10):1492-1501. PMID: 27480492

Links of Interest